Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical
NCT ID: NCT06643494
Last Updated: 2025-03-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
PHASE1/PHASE2
100 participants
INTERVENTIONAL
2024-08-15
2026-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
NCT00006359
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
NCT00936390
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
NCT00005044
Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer
NCT00003124
External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
NCT00388804
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will:
Take N-111 or a placebo by mouth every day for the duration of the ADT + EBR therapy. Fill out the self-evaluation reporting form weekly during EBR therapy and every three months during ADT therapy to assess their symptoms or lack of symptoms.
The patients will see a physician once a week during the EBR therapy and once every three months for the duration of the ADT therapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
SUPPORTIVE_CARE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
N-111
Nutraceutical N-111 in conjunction with ADT + EBR will be given in this arm, once per day with breakfast.
N-111
A combination of Acetogenins
Placebo
A placebo that is inert but appears to look the same as the active comparator in conjunction with ADT + EBR, given once per day with breakfast.
Placebo
Placebo
Control
The control group will proceed with the ADT + EBR treatment without taking the active compactor or the placebo.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
N-111
A combination of Acetogenins
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
40 Years
80 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Optimal Health Research
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alan Jeppsen, MD
Role: STUDY_CHAIR
Optimal Health Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Optimal Health Research
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RLP051624.
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.